Quick Takeaways: Why It Matters? ECO’s licence of Vaxinano’s late‑stage sheep toxoplasmosis vaccine gives it a low‑cost, de‑risked way to add a high‑value preventative product that directly tackles a major cause of abortion and lamb losses, with peak sales estimated a...
Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
